It was the company that approached Israel and offered the vaccine

“Israel was one of the first countries we approached and gave them the opportunity to purchase the corona vaccines early, because we anticipated the high demand that would be created later on,” Dr. Tal Zacks, the chief scientist of the American Modern Company, which published impressive results in the experiment, reveals tonight. In fact, in contrast to the Israeli government’s narrative of being able to identify the need for vaccines early, it turns out that Modern was the one that initiated the vaccine purchase deal in which the state paid about $ 60 million to secure the first million doses.

Read more in Calcalist:

According to Zacks, Israel will be among the first to receive the vaccines from the European production facility of the company owned by the Swiss Lonza. The U.S. that gets priority with the 100 million first batches is supposed to get the vaccines from the U.S. manufacturing plant. He said, “That’s exactly why we set up the parallel production line in Europe, so we can meet the commitments.”

The modernity vaccine Photo: Ai

Can any pharmaceutical company with a manufacturing plant, such as Teva, produce your vaccine if it receives FDA approval according to a specific specification?

“Teva will not be able to produce the vaccine because it is not a ‘recipe’ where you can simply produce the substance. It took us years to learn how to build the vaccine and it also took us months to train the Lonza people to produce it. We also send the best people from us to teach “The process and like any young technology it takes time, and it is a difficult project that also undergoes many patents. A lot depends on the raw materials, the production efficiency and this is the first time that the vaccine is now being produced.”

How reliable are the current results – their level of significance? Who decides when the interim results are published?

“This whole issue is managed by an independent committee and it is the one that examines and decides when the numbers allow publication. In principle, the data were significant even when there were 53 patients in the trial, but we waited for 95 patients.”

Do the experimenters lead a normal lifestyle after receiving the vaccine or can a situation arise where they are overly careful and therefore not exposed to verified patients at all?

“The experimenters lead a completely normal lifestyle, some even work in the health system. Everyone is exposed to the disease. In any case, these are very significant results that indicate an efficiency of 94.5%.”

Tal Zacks Photo: Youtube / Moderna

And what about the infectivity of those who are vaccinated? Is there already information about their ability to infect others even though they themselves are vaccinated?

“At this stage it is too early to say, these are data that we will need to check when blood tests are done for those who have already been vaccinated and see their antibodies.”

And what about the effectiveness of the vaccine over time? Should everything be created in a situation where the vaccine is effective at high levels but does not last more than three months?

“I do not think it is likely, there are very high levels of antibodies in the blood that clinical trials have shown, and that gives confidence and optimism. Of course we will have to follow the experimenters but the high efficiency gives light at the end of the tunnel.”

And to the question of storage and transportation – your vaccine and that of Pfizer are built on the same method and even showed similar efficiency rates, require completely different cooling conditions. Yours holds half a year in a regular freezer and also a month in a regular refrigerator while the Pfizer vaccine requires a cooling of minus 70 degrees. How do you explain the gap?

“We are investing a lot in improving production capabilities and that includes patents also in the field of preservation and finding the temperature at which we are able to keep the vaccine. As for Pfizer’s vaccine I can not speak.”

Still, to date you have not been able to bring to market any vaccine based on the mRNA method that “teaches” the body to produce antibodies without injecting the attenuated or killed virus into it.

“Vaccines take years to develop, each phase takes a long time and requires many regulatory approvals. So even our most advanced vaccine is starting the third stage now. In the case of the corona we have received approvals to perform clinical phases simultaneously and authorities have approved many processes quickly. To Corona for the usual vaccines. “

These were the details of the news It was the company that approached Israel and offered the vaccine for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

NEXT US Fed holds key rate steady for fourth straight meeting